Compare Cassava Sciences Inc (FLNA) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Lowe`s Companies Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Lowe`s Companies Inc trades at $214 (market cap $117.56B). The key difference: Lowe`s Companies Inc is far larger — about 2212.3× Cassava Sciences Inc's market cap, and Lowe`s Companies Inc pays a 2.38% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LOW | |
|---|---|---|
Market Cap | $53.14M | $117.56B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $287.39 |
52-Week Low | $1.09 | $206.62 |
Enterprise Value | -$33.43M | $159.31B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Lowe's Companies (LOW) trades at $213.81, up 2.94% on the day, with a bearish technical signal but strong analyst consensus. Recent earnings beats and a 7.51% net income margin highlight operational strength, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. The stock shows support near $205 and resistance at $215, with a consensus price target of $260.88 implying 22% upside. Dividend growth remains a key attraction, with the quarterly payout rising to $1.25.
LOW offers value with a P/E of 17.72 and bullish analyst sentiment (60.79% buy ratings), but faces risks from high debt levels and competitive pressures. The outlook hinges on execution in the professional segment and interest rate sensitivity, with near-term volatility expected around Q2 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
